

## Kinetics of the platelet release reaction induced by collagen

A.H. DRUMMOND\* & J.L. GORDON


*Department of Pathology, University of Cambridge*

Collagen induces platelet aggregation and releases constituents from platelet granules, but the relationship between these responses has not been established. We have investigated this by measuring the release of 5-hydroxytryptamine (5-HT) and total adenine nucleotides from rat blood platelets over a period of 2 min after the addition of varying concentrations of collagen.

Platelet aggregation induced by collagen extract (CE) (Gordon & Gresham, 1972) was measured photometrically in rat citrated platelet-rich plasma. Adenine nucleotides (AN) and 5-HT in platelets and in supernatant plasma were measured fluorimetrically (Gordon & Drummond, 1974; Drummond & Gordon, 1974).

With a CE concentration (34  $\mu\text{g}/\text{ml}$ ) giving a maximal aggregation response there was progressive release of both AN and 5-HT (maximal after 2 minutes). With lower concentrations of CE, release of 5-HT and AN was divided into two kinetically distinct components. The first release occurred within 10 s of adding the CE, well before platelet aggregation began, and the second release paralleled the aggregation response. There was appreciable re-uptake of the initially released 5-HT before the second phase of release occurred (Figure 1). Platelet aggregation and the second phase of release were inhibited in parallel by EDTA (7.5 mM) and Colchicine (2.5 mM), but the initial release and the platelet shape change (which precedes aggregation) were unaffected. Prostaglandin  $\text{E}_1$  (30 nM) and the pyrimido-pyrimidine derivative VK 774 (100  $\mu\text{M}$ ) inhibited both phases of release as well as the platelet shape change and the aggregation response.

Previous studies have failed to demonstrate two distinct phases of release with an intervening stage



**Fig. 1** Platelet aggregation and release of 5-hydroxytryptamine (5-HT) induced by collagen extract (CE). (●) Intracellular; (○) extracellular. Note initial release followed by partial reuptake and then secondary release. Points shown are means  $\pm$  s.e. of six determinations. The content of 5-HT in platelets from control samples was  $1.12 \mu\text{g}/10^9$  cells.

of re-uptake (Packham, Guccione, Chang & Mustard, 1973; Weiss, Rogers & Brand, 1973). The reasons for this will be discussed. Our results support the concept that collagen induces platelet aggregation by releasing platelet constituents (Haslam, 1967). We suggest that the initial release is associated with platelet-collagen adhesion; both processes occur rapidly and are independent of extracellular calcium.

A.H.D. is an M.R.C. scholar.

## References

- DRUMMOND, A.H. & GORDON, J.L. (1974). Rapid, sensitive microassay for platelet 5-hydroxytryptamine. *Thromb. Diath. haemorrh.* (in press).
- GORDON, J.L. & DRUMMOND, A.H. (1974). A simple fluorimetric microassay for adenine compounds in platelets and plasma and its application to studies on the platelet release reaction. *Biochem. J.*, **138**, 165-169.
- GORDON, J.L. & GRESHAM, G.A. (1972). The measurement of platelet aggregation in small blood samples. *Atherosclerosis*, **15**, 383-386.
- HASLAM, R.J. (1967). Mechanisms of blood platelet aggregation. In: *Physiology of Hemostasis and Thrombosis*. Ed. Johnson, S.A. & Seegers, W.H., Springfield, Illinois: Charles C. Thomas.
- PACKHAM, M.A., GUCCIONE, M.A., CHANG, P.-L. & MUSTARD, J.F. (1973). Platelet aggregation and release: effects of low concentrations of thrombin or collagen. *Am. J. Physiol.*, **225**, 38-47.
- WEISS, H.J., ROGERS, J. & BRAND, H. (1973). Defective ristocetin-induced platelet aggregation in Von Willebrand's disease and its correction by Factor VIII. *J. clin. Invest.*, **52**, 2697-2707.

## Receptors for 5-hydroxytryptamine and noradrenaline in rabbit aorta and central ear artery

EIRA APPERLEY, P.P.A. HUMPHREY\* & G.P. LEVY

Department of Pharmacology, Allen & Hanburys Research Ltd, Ware, Herts

There is considerable evidence implicating 5-hydroxytryptamine (5-HT) in the vascular disturbances associated with migraine (Lance, Anthony & Hinterberger, 1970). As part of a

study into the pharmacology of drugs used in the treatment of migraine we have examined the characteristics of 5-HT receptors in vascular smooth muscle from rabbit aorta and ear artery. In addition, the pharmacological characteristics of the  $\alpha$ -adrenoceptors in these two tissues were examined.

Preparations were obtained from New Zealand white rabbits anaesthetized with pentobarbitone sodium (36 mg/kg i.v.). Isolated aortic strips and central ear arteries were set up as described by Furchgott & Bhadrakom (1953) and de la Lande & Rand (1965) respectively. Tissues were maintained in Krebs solution gassed with 5% CO<sub>2</sub> in O<sub>2</sub> at

**Table 1** Interactions between agonists and antagonists in rabbit vascular smooth muscle

Artery	Antagonist	$pA_2$ (30 min) against				
		5-HT	Methysergide	Noradrenaline	KCl	Vasopressin
Aorta	Methysergide	8.49 (7.85-9.14)	—	5.29 (4.95-5.63)	<4.6	—
Aorta	Phentolamine	6.21 (5.52-6.90)	—	7.96 (7.76-8.16)	<4.6	—
Central ear	Pizotifen	6.79 (6.39-7.18)	6.95 (6.48-7.42)	6.57 (6.15-6.98)	—	<5.4
Central ear	Phentolamine	8.41 (7.99-8.83)	8.25 (7.96-8.54)	8.09 (7.54-8.64)	—	<7.3

In the aortic strip both agonists and antagonists were added to the bathing solution. In the ear artery the agonists were administered as a bolus injection close to the artery and antagonists added directly to the perfusion reservoir.

The primary and secondary responses to 5-HT in the central ear artery were antagonized to the same extent by pizotifen and phentolamine. The results for the primary phase are presented in Table 1. In the case of methysergide the primary phase was often poorly defined and only the secondary phase was examined.

Each value quoted is the mean (95% confidence limits) of 4-8 separate estimates.